The present invention relates to at least one glycosylation inhibitor for use in combination with CAR cell therapy. Preferably, the glycosylation inhibitor improves the therapeutic potential of the CAR cell therapy. The invention also relates to a pharmaceutical composition and to population or subpopulation of CAR cell that has been contacted with at least one glycosylation inhibitor.

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7.sup.+ malignancies.

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.

An OCTS-based CAR-T vector for treating pancreatic cancer and malignant mesothelioma includes lentiviral skeleton plasmid, human EF1α promoter (SEQ ID NO: 14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody; the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO: 15), PDL1 single-chain antibody light chain VL (SEQ ID NO: 16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO: 17), mesothelin single-chain antibody light chain VL (SEQ ID NO: 18), mesothelin single-chain antibody heavy chain VH (SEQ ID NO: 19), antibody Inner-Linker (SEQ ID NO: 20), single-chain antibody Inter-Linker (SEQ ID NO: 21), CD8 Hinge chimeric receptor linker (SEQ ID NO: 22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO: 23), TCR chimeric receptor T cell activation domain (SEQ ID NO: 26) and chimeric receptor co-stimulator domain.

A chimeric antigen receptor targeting to human NKG2DL, its encoding sequence, and its modified immune response cells, and the preparation and application thereof are provided. This invention constructs a chimeric antigen receptor targeting to NKG2DL and its modified immune response cell based on the NKG2D molecule. The amino acid sequence of the chimeric antigen receptor targeting the human NKG2DL is sequentially connected by the following amino acid sequences from an amino terminal to a carboxy terminal: an amino acid sequence of a guiding sequence, an amino acid sequence of human NKG2D, an amino acid sequence of a human CD8 hinge region, an amino acid sequence of a human CD8 transmembrane region, an amino acid sequence of a human 4-1BB intracellular domain and an amino acid sequence of a human CD3 zeta domain.

The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable TRAIL polypeptide.

Provided are methods for preventing initiation and/or progression of gastrin-associated tumors and/or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and/or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and/or development of a gastrin-associated tumor or cancer and/or for preparing medicaments therefor, and compositions for use in preventing initiation and/or development of gastrin-associated tumors and/or cancers and/or precancerous lesions thereof.

The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.

Provided herein are methods and compositions related to bacteria of genus Burkholderia useful as therapeutic agents.